Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
Uro-Oncology
COMMENTED
Related content
Uro-Oncology
Systemic treatments for high-risk localized prostate cancer
Nat Rev Urol.
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D
doi: 10.1038/s41585-018-0017-x.
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Eur Urol.
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A
doi: 10.1016/
COMMENTED
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.012.
Uro-Oncology
Systematic Review of Time to Definitive Treatment for Intermediate-Risk and High-Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?
J Urol
Nguyen DD, Haeuser L, Paciotti M, Reitblat C, Cellini J, Lipsitz SR, Kibel AS, Choudhury AD, Cone EB, Trinh QD
doi: 10.1097/JU.0000000000001601
Further Publications UrologyFurther Publications Gynecology
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Lancet.
Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes MR, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar MKB, Tierney JF, ARTISTIC Meta-analysis Group.
doi: 10.1016/S0140-6736(20)31952-8.
Uro-Oncology
Radical Prostatectomy or Radiotherapy for High and Very High Risk Prostate Cancer: A Multidisciplinary Clinic Experience of Patients Eligible for Either Treatment
BJU Int.
Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF
doi: 10.1111/bju.14780.
Uro-Oncology
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Prostate Cancer Prostatic Dis
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI
doi: 10.1038/s41391-021-00395-4
Uro-Oncology
Changes in treatment and mortality in men with locally advanced prostate cancer between 2000-2016. Nationwide, population-based study in Sweden
BJU Int.
Orrason AW, Westerberg M, Garmo H, Franck Lissbrant I, Robinson D, Stattin P
doi: 10.1111/bju.15077.
Uro-Oncology
Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review
World J Urol.
Marra G, Gontero P, Walz JC, Sivaraman A, Tourinho-Barbosa R, Cathelineau X, Sanchez-Salas R
doi: 10.1007/s00345-